Company registration number SC259837 (Scotland)
BURNS PHARMACY LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
BURNS PHARMACY LIMITED
CONTENTS
Page
Company information
1
Strategic report
2
Directors' report
3 - 4
Independent auditor's report
5 - 7
Group statement of comprehensive income
8
Group balance sheet
9
Company balance sheet
10 - 11
Group statement of changes in equity
12
Company statement of changes in equity
13
Group statement of cash flows
14
Notes to the financial statements
15 - 29
BURNS PHARMACY LIMITED
COMPANY INFORMATION
- 1 -
Directors
Mrs C Burns
Mr S Burns
Company number
SC259837
Registered office
153 Ayr Road
Prestwick
Ayrshire
KA9 1TP
Auditor
Consilium Audit Limited
169 West George Street
Glasgow
Scotland
G2 2LB
BURNS PHARMACY LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
The directors present the strategic report for the year ended 31 March 2025.
Review of the business
The Group trades as 'Burns Pharmacy' operating in Scotland. Burns Pharmacy has established itself as one of Scotland's most progressive and resilient community pharmacy groups.
There has been a slight increase in Group turnover compared to the prior year from £8,699k to £9,214k. At the year-end the Group had shareholders funds and distributable profits of £990k (2024: £1,934k). The directors therefore believe the Group's position to be satisfactory.
During the year, the Directors reviewed the carrying value of goodwill and concluded that it should be amortised over a remaining useful life of four years. Accordingly, amortisation was recognised in the period.
Principal risks and uncertainties
Financial Risk Management
The Group monitors working capital strictly. No hedging of foreign currency movements is considered appropriate and the company has little direct exposure to movements in foreign currencies.
The Directors consider that the financial controls in place are more than adequate for management of financial risk.
Key performance indicators
The directors use KPI's to measure return on capital employed as well as gross and net profit margins along with other financial departmental KPI's to monitor the group's development and performance during the year as well as financial position at year end. The KPI's are cascaded through each trading department and are in line with management expectations throughout the business.
| | | | |
| | | | |
| | | | |
Net profit / (loss) before tax and amortisation % | | | | |
Net profit / (loss) after tax % | | | | |
.............................................
Mrs C Burns
Director
23 December 2025
BURNS PHARMACY LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
The directors present their annual report and financial statements for the year ended 31 March 2025.
Principal activities
The principal activity of the company and group continued to be that of pharmacy dispensing and retail sales.
Results and dividends
The results for the year are set out on page 8.
Ordinary dividends were paid amounting to £144,000 (2024: £133,005). The directors do not recommend payment of a further dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Mrs C Burns
Mr S Burns
Auditor
Consilium Audit Limited were appointed as auditor to the group and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.
Statement of directors' responsibilities
The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.
BURNS PHARMACY LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
On behalf of the board
..............................................
Mrs C Burns
Director
23 December 2025
BURNS PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF BURNS PHARMACY LIMITED
- 5 -
Qualified opinion on financial statements
We have audited the financial statements of Burns Pharmacy Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements:
give a true and fair view of the state of the group's and the parent company's affairs as at 31 March 2025 and of the group's loss for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for qualified opinion
We were not appointed as auditor of the Company until after 31 March 2025. Accordingly, we did not attend the stock counts at either 31 March 2025 or 31 March 2024. We were also unable to satisfy ourselves by alternative means concerning the inventory quantities, which were included in the balance sheet at £284,869 (2024: £291,047).
Consequently, we were unable to determine whether any adjustment to this amount was necessary at either year end, or whether there was any consequential effect on the cost of sales for either year.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
BURNS PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF BURNS PHARMACY LIMITED
- 6 -
Opinions on other matters prescribed by the Companies Act 2006
Except for the possible effects of the matters detailed in the basis for qualified opinion section of our report, in our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In respect solely of the limitation on our work relating to stock, described above:
we have not obtained all the information and explanations that we considered necessary for the purpose of our audit; and
we were unable to determine whether adequate accounting records had been maintained.
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:
BURNS PHARMACY LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF BURNS PHARMACY LIMITED
- 7 -
We ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations.
We identified the laws and regulations applicable to the group and company through discussions with the director and management and from our knowledge of the regulatory environment relevant to the group and company.
We assessed the extent of compliance with laws and regulations through making enquiries of management and inspecting legal correspondence.
We assessed the susceptibility of the group's and company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by making enquiries of management as to where they considered there was susceptibility to fraud and their knowledge of actual, suspected and alleged fraud.
To address the risk of fraud through management bias and override of controls, we tested journal entries to identify unusual transactions, we assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias and we investigated the rationale behind significant or unusual transactions.
There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence.
Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Brian Thomson BA(Hons) CA (Senior Statutory Auditor)
For and on behalf of Consilium Audit Limited, Statutory Auditor
169 West George Street
Glasgow
G2 2LB
Scotland
23 December 2025
BURNS PHARMACY LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
- 8 -
2025
2024
Notes
£
£
Turnover
3
9,213,815
8,699,036
Cost of sales
(5,412,134)
(5,625,770)
Gross profit
3,801,681
3,073,266
Administrative expenses
(4,067,658)
(2,462,174)
Other operating income
36,086
2,638
Operating (loss)/profit
4
(229,891)
613,730
Interest receivable and similar income
7
107,971
Interest payable and similar expenses
8
(380,488)
(319,338)
(Loss)/profit before taxation
(610,379)
402,363
Tax on (loss)/profit
9
(189,689)
(247,465)
(Loss)/profit for the financial year
(800,068)
154,898
(Loss)/profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company.
The notes on pages 15 to 29 form part of these financial statements.
BURNS PHARMACY LIMITED
GROUP BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 9 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
11
3,825,132
5,140,721
Tangible assets
12
2,042,794
1,896,251
5,867,926
7,036,972
Current assets
Stocks
15
284,867
291,047
Debtors
16
1,131,216
1,184,501
Cash at bank and in hand
852,343
729,798
2,268,426
2,205,346
Creditors: amounts falling due within one year
17
(1,697,450)
(1,940,146)
Net current assets
570,976
265,200
Total assets less current liabilities
6,438,902
7,302,172
Creditors: amounts falling due after more than one year
18
(5,160,534)
(5,105,729)
Provisions for liabilities
Deferred tax liability
21
288,439
262,446
(288,439)
(262,446)
Net assets
989,929
1,933,997
Capital and reserves
Called up share capital
23
1
1
Profit and loss reserves
989,928
1,933,996
Total equity
989,929
1,933,997
The notes on pages 15 to 29 form part of these financial statements.
The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
23 December 2025
..............................................
Mrs C Burns
Director
Company registration number SC259837 (Scotland)
BURNS PHARMACY LIMITED
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 10 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
11
3,789,132
5,104,721
Tangible assets
12
2,042,794
1,896,251
Investments
13
1
1
5,831,927
7,000,973
Current assets
Stocks
15
284,867
291,047
Debtors
16
1,106,433
1,157,341
Cash at bank and in hand
852,336
729,798
2,243,636
2,178,186
Creditors: amounts falling due within one year
17
(1,867,519)
(2,107,844)
Net current assets
376,117
70,342
Total assets less current liabilities
6,208,044
7,071,315
Creditors: amounts falling due after more than one year
18
(5,160,534)
(5,105,729)
Provisions for liabilities
Deferred tax liability
21
288,439
262,446
(288,439)
(262,446)
Net assets
759,071
1,703,140
Capital and reserves
Called up share capital
23
1
1
Profit and loss reserves
759,070
1,703,139
Total equity
759,071
1,703,140
The notes on pages 15 to 29 form part of these financial statements.
As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £800,069 (2024: £75,959 loss).
BURNS PHARMACY LIMITED
COMPANY BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
31 March 2025
- 11 -
The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
23 December 2025
..............................................
Mrs C Burns
Director
Company registration number SC259837 (Scotland)
BURNS PHARMACY LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 12 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 April 2023
1
1,912,103
1,912,104
Year ended 31 March 2024:
Profit and total comprehensive income
-
154,898
154,898
Dividends
10
-
(133,005)
(133,005)
Balance at 31 March 2024
1
1,933,996
1,933,997
Year ended 31 March 2025:
Loss and total comprehensive income
-
(800,068)
(800,068)
Dividends
10
-
(144,000)
(144,000)
Balance at 31 March 2025
1
989,928
989,929
The notes on pages 15 to 29 form part of these financial statements.
BURNS PHARMACY LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 13 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 April 2023
1
1,912,103
1,912,104
Year ended 31 March 2024:
Loss and total comprehensive income for the year
-
(75,959)
(75,959)
Dividends
10
-
(133,005)
(133,005)
Balance at 31 March 2024
1
1,703,139
1,703,140
Year ended 31 March 2025:
Profit and total comprehensive income
-
(800,069)
(800,069)
Dividends
10
-
(144,000)
(144,000)
Balance at 31 March 2025
1
759,070
759,071
The notes on pages 15 to 29 form part of these financial statements.
BURNS PHARMACY LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025
- 14 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
25
1,184,648
1,029,666
Interest paid
(380,488)
(319,338)
Income taxes paid
(151,019)
(7,121)
Net cash inflow from operating activities
653,141
703,207
Investing activities
Purchase of intangible assets
-
(4,440,019)
Purchase of tangible fixed assets
(226,411)
(528,542)
Proceeds from disposal of tangible fixed assets
-
4,169
Interest received
107,971
Net cash used in investing activities
(226,411)
(4,856,421)
Financing activities
Proceeds from new bank loans
-
5,309,500
Repayment of bank loans
(82,732)
(1,130,650)
Payment of finance leases obligations
(38,610)
-
Amounts withdrawn by directors
(30,691)
(3,690)
Dividends paid to equity shareholders
(144,000)
(133,005)
Net cash (used in)/generated from financing activities
(296,033)
4,042,155
Net increase/(decrease) in cash and cash equivalents
130,697
(111,059)
Cash and cash equivalents at beginning of year
721,646
832,705
Cash and cash equivalents at end of year
852,343
721,646
Relating to:
Cash at bank and in hand
852,343
729,798
Bank overdrafts included in creditors payable within one year
-
(8,152)
The notes on pages 15 to 29 form part of these financial statements.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 15 -
1
Accounting policies
Company information
Burns Pharmacy Limited (“the company”) is a private limited company domiciled and incorporated in Scotland. The registered office is 153 Ayr Road, Prestwick, Ayrshire, KA9 1TP.
The group consists of Burns Pharmacy Limited and all of its subsidiaries.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.
1.2
Business combinations
In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.
Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 16 -
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company Burns Pharmacy Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.
1.4
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.5
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Dispensing income is recognised at the time prescriptions are made up. Shop sales are recognised at the time ownership of goods is transferred.
1.6
Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 4 years.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.
1.7
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 17 -
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Freehold land and buildings
2% & 5% straight line
Plant and equipment
5% straight line
Fixtures and fittings
20% reducing balance
Computers
33% straight line
Motor vehicles
25% reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
1.8
Fixed asset investments
Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.
In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.
A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
Entities in which the group has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
1.9
Impairment of fixed assets
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.
1.10
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 18 -
1.11
Financial instruments
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.12
Equity instruments
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
1.13
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 19 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.14
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.15
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.16
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
2
Judgements and key sources of estimation uncertainty
In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 20 -
3
Turnover and other revenue
2025
2024
£
£
Other revenue
Interest income
-
107,971
All turnover is generated in the UK.
4
Operating (loss)/profit
2025
2024
£
£
Operating (loss)/profit for the year is stated after charging/(crediting):
Fees payable to the group's auditor for the audit of the group's financial statements
17,000
-
Depreciation of owned tangible fixed assets
138,954
142,302
Depreciation of tangible fixed assets held under finance leases
34,749
-
Profit on disposal of tangible fixed assets
(43,785)
(3,533)
Amortisation of intangible assets
1,315,589
285,035
Operating lease charges
107,687
51,283
5
Employees
The average monthly number of persons (including directors) employed by the group and company during the year was:
Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
87
97
87
97
Their aggregate remuneration comprised:
Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
1,754,987
1,398,113
1,754,987
1,398,113
Social security costs
150,095
102,065
150,095
102,065
Pension costs
38,523
38,485
38,523
38,485
1,943,605
1,538,663
1,943,605
1,538,663
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 21 -
6
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
17,238
17,238
7
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
107,971
8
Interest payable and similar expenses
2025
2024
£
£
Interest on bank overdrafts and loans
373,358
319,251
Other interest
7,130
87
Total finance costs
380,488
319,338
9
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
163,696
130,769
Adjustments in respect of prior periods
(15,088)
Total current tax
163,696
115,681
Deferred tax
Origination and reversal of timing differences
25,993
131,784
Total tax charge
189,689
247,465
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
9
Taxation
(Continued)
- 22 -
The actual charge for the year can be reconciled to the expected (credit)/charge for the year based on the profit or loss and the standard rate of tax as follows:
2025
2024
£
£
(Loss)/profit before taxation
(610,379)
402,363
Expected tax (credit)/charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
(152,595)
100,591
Tax effect of expenses that are not deductible in determining taxable profit
377,935
30,179
Permanent capital allowances in excess of depreciation
(35,651)
131,784
Under/(over) provided in prior years
(15,089)
Taxation charge
189,689
247,465
10
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Final paid
144,000
133,005
11
Intangible fixed assets
Group
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
6,630,046
Amortisation and impairment
At 1 April 2024
1,489,325
Amortisation charged for the year
1,315,589
At 31 March 2025
2,804,914
Carrying amount
At 31 March 2025
3,825,132
At 31 March 2024
5,140,721
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
11
Intangible fixed assets
(Continued)
- 23 -
Company
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
6,594,046
Amortisation and impairment
At 1 April 2024
1,489,325
Amortisation charged for the year
1,315,589
At 31 March 2025
2,804,914
Carrying amount
At 31 March 2025
3,789,132
At 31 March 2024
5,104,721
12
Tangible fixed assets
Group
Freehold land and buildings
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 April 2024
1,579,608
420,628
102,980
50,969
180,898
2,335,083
Additions
177,952
235,808
22,323
21,991
458,074
Disposals
(178,831)
(24,153)
(202,984)
At 31 March 2025
1,757,560
477,605
125,303
50,969
178,736
2,590,173
Depreciation and impairment
At 1 April 2024
57,891
216,872
68,182
12,703
83,184
438,832
Depreciation charged in the year
60,430
60,612
8,231
16,988
27,442
173,703
Eliminated in respect of disposals
(43,218)
(21,938)
(65,156)
At 31 March 2025
118,321
234,266
76,413
29,691
88,688
547,379
Carrying amount
At 31 March 2025
1,639,239
243,339
48,890
21,278
90,048
2,042,794
At 31 March 2024
1,521,717
203,756
34,798
38,266
97,714
1,896,251
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
12
Tangible fixed assets
(Continued)
- 24 -
Company
Freehold land and buildings
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 April 2024
1,579,608
420,628
102,980
50,969
180,898
2,335,083
Additions
177,952
235,808
22,323
21,991
458,074
Disposals
(178,831)
(24,153)
(202,984)
At 31 March 2025
1,757,560
477,605
125,303
50,969
178,736
2,590,173
Depreciation and impairment
At 1 April 2024
57,891
216,872
68,182
12,703
83,184
438,832
Depreciation charged in the year
60,430
60,612
8,231
16,988
27,442
173,703
Eliminated in respect of disposals
(43,218)
(21,938)
(65,156)
At 31 March 2025
118,321
234,266
76,413
29,691
88,688
547,379
Carrying amount
At 31 March 2025
1,639,239
243,339
48,890
21,278
90,048
2,042,794
At 31 March 2024
1,521,717
203,756
34,798
38,266
97,714
1,896,251
The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.
Group
Company
2025
2024
2025
2024
£
£
£
£
Plant and equipment
196,914
196,914
13
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
14
1
1
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
13
Fixed asset investments
(Continued)
- 25 -
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024 and 31 March 2025
1
Carrying amount
At 31 March 2025
1
At 31 March 2024
1
14
Subsidiaries
Details of the company's subsidiaries at 31 March 2025 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
LP North Twelve Limited
153 Ayr Road, Prestwick, Scotland, KA9 1TP
Ordinary
100.00
15
Stocks
Group
Company
2025
2024
2025
2024
£
£
£
£
Raw materials and consumables
284,867
291,047
284,867
291,047
16
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
733,025
706,263
733,025
706,263
Amounts owed by group undertakings
-
-
-
12,574
Other debtors
263,714
278,603
238,931
238,869
Prepayments and accrued income
134,477
199,635
134,477
199,635
1,131,216
1,184,501
1,106,433
1,157,341
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 26 -
17
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
19
226,376
236,928
226,376
236,906
Obligations under finance leases
20
57,916
57,916
Trade creditors
1,055,499
1,421,397
1,052,887
1,419,042
Amounts owed to group undertakings
2,898
Corporation tax payable
163,696
151,019
163,696
151,019
Other taxation and social security
33,915
28,784
30,987
26,148
Other creditors
50,850
52,160
22,729
24,039
Accruals and deferred income
109,198
49,858
310,030
250,690
1,697,450
1,940,146
1,867,519
2,107,844
18
Creditors: amounts falling due after more than one year
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Bank loans and overdrafts
19
5,025,397
5,105,729
5,025,397
5,105,729
Obligations under finance leases
20
135,137
135,137
5,160,534
5,105,729
5,160,534
5,105,729
19
Loans and overdrafts
Group
Company
2025
2024
2025
2024
£
£
£
£
Bank loans
5,251,773
5,334,505
5,251,773
5,334,505
Bank overdrafts
8,152
8,130
5,251,773
5,342,657
5,251,773
5,342,635
Payable within one year
226,376
236,928
226,376
236,906
Payable after one year
5,025,397
5,105,729
5,025,397
5,105,729
The long-term loans are secured by fixed charges over the Prestwick, Ayr and Mossblown properties and a life assurance policy in the name of Stuart Patrick Burns.
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 27 -
20
Finance lease obligations
Group
Company
2025
2024
2025
2024
£
£
£
£
Future minimum lease payments due under finance leases:
Within one year
57,916
57,916
In two to five years
135,137
135,137
193,053
-
193,053
-
Finance lease payments represent the rentals payable by the company or group for certain items of plant and machinery. The leases include purchase options at the end of the lease term, and there are no restrictions on the use of the related assets. The average lease term is four years. All leases are on a fixed repayment basis, and no arrangements have been made for contingent rental payments. The finance leases are secured solely on the assets to which they relate.
21
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:
Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
289,292
262,446
Retirement benefit obligations
(853)
-
288,439
262,446
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
289,292
262,446
Retirement benefit obligations
(853)
-
288,439
262,446
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 April 2024
262,446
262,446
Charge to profit or loss
25,993
25,993
Liability at 31 March 2025
288,439
288,439
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 28 -
22
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
38,523
38,485
A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
23
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Total share capital of 1p each
100
100
1
1
The share capital is classified as follows:
90 Ordinary 1p shares
10 A Ordinary 1p shares
24
Controlling party
During the year, the Company was under the control of its shareholders. The Company was ultimately controlled by Catherine Burns, who held a controlling interest despite the presence of minority shareholders.
Following a transfer of all issued shares to Delta Pharmacy Limited on 17 December 2025, the Company became a wholly owned subsidiary of that entity. The ultimate controlling party is Stuart Burns, as the majority shareholder of the parent.
25
Cash generated from group operations
2025
2024
£
£
(Loss)/profit after taxation
(800,068)
154,898
Adjustments for:
Taxation charged
189,689
247,465
Finance costs
380,488
319,338
Investment income
(107,971)
Loss/(gain) on disposal of tangible fixed assets
137,828
(3,533)
Amortisation and impairment of intangible assets
1,315,589
285,035
Depreciation and impairment of tangible fixed assets
173,703
142,302
Movements in working capital:
Decrease/(increase) in stocks
6,180
(76,047)
Decrease/(increase) in debtors
67,416
(618,030)
(Decrease)/increase in creditors
(286,177)
686,209
Cash generated from operations
1,184,648
1,029,666
BURNS PHARMACY LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 29 -
26
Analysis of changes in net debt - group
1 April 2024
Cash flows
New finance leases
31 March 2025
£
£
£
£
Cash at bank and in hand
729,798
122,545
-
852,343
Bank overdrafts
(8,152)
8,152
-
721,646
130,697
-
852,343
Borrowings excluding overdrafts
(5,334,505)
82,732
-
(5,251,773)
Obligations under finance leases
-
38,610
(231,663)
(193,053)
(4,612,859)
252,039
(231,663)
(4,592,483)
2025-03-312024-04-01falsefalseCCH SoftwareCCH Accounts Production 2025.300Mrs C BurnsMr S BurnsfalseSC259837bus:Consolidated2024-04-012025-03-31SC2598372024-04-012025-03-31SC259837bus:Director12024-04-012025-03-31SC259837bus:Director22024-04-012025-03-31SC259837bus:RegisteredOffice2024-04-012025-03-31SC2598372025-03-31SC259837bus:Consolidated2025-03-31SC259837bus:Consolidated2023-04-012024-03-31SC2598372023-04-012024-03-31SC259837core:Goodwillbus:Consolidated2025-03-31SC259837core:Goodwillbus:Consolidated2024-03-31SC259837core:Goodwill2025-03-31SC259837core:Goodwill2024-03-31SC259837bus:Consolidated2024-03-31SC2598372024-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2025-03-31SC259837core:PlantMachinerybus:Consolidated2025-03-31SC259837core:FurnitureFittingsbus:Consolidated2025-03-31SC259837core:ComputerEquipmentbus:Consolidated2025-03-31SC259837core:MotorVehiclesbus:Consolidated2025-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-31SC259837core:PlantMachinerybus:Consolidated2024-03-31SC259837core:FurnitureFittingsbus:Consolidated2024-03-31SC259837core:ComputerEquipmentbus:Consolidated2024-03-31SC259837core:MotorVehiclesbus:Consolidated2024-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssets2025-03-31SC259837core:PlantMachinery2025-03-31SC259837core:FurnitureFittings2025-03-31SC259837core:ComputerEquipment2025-03-31SC259837core:MotorVehicles2025-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-31SC259837core:PlantMachinery2024-03-31SC259837core:FurnitureFittings2024-03-31SC259837core:ComputerEquipment2024-03-31SC259837core:MotorVehicles2024-03-31SC259837core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-03-31SC259837core:CurrentFinancialInstrumentsbus:Consolidated2024-03-31SC259837core:ShareCapitalbus:Consolidated2025-03-31SC259837core:ShareCapitalbus:Consolidated2024-03-31SC259837core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-31SC259837core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-31SC259837core:ShareCapital2025-03-31SC259837core:ShareCapital2024-03-31SC259837core:RetainedEarningsAccumulatedLosses2025-03-31SC259837core:RetainedEarningsAccumulatedLosses2024-03-31SC259837core:ShareCapitalbus:Consolidated2023-03-31SC2598372023-03-31SC259837core:ShareCapital2023-03-31SC259837core:RetainedEarningsAccumulatedLosses2023-03-31SC259837bus:Consolidated2023-03-31SC259837core:Goodwill2024-04-012025-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssets2024-04-012025-03-31SC259837core:PlantMachinery2024-04-012025-03-31SC259837core:FurnitureFittings2024-04-012025-03-31SC259837core:ComputerEquipment2024-04-012025-03-31SC259837core:MotorVehicles2024-04-012025-03-31SC259837core:UKTaxbus:Consolidated2024-04-012025-03-31SC259837core:UKTaxbus:Consolidated2023-04-012024-03-31SC259837bus:Consolidated12024-04-012025-03-31SC259837bus:Consolidated12023-04-012024-03-31SC259837core:Goodwillbus:Consolidated2024-03-31SC259837core:Goodwill2024-03-31SC259837core:Goodwillbus:Consolidated2024-04-012025-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-03-31SC259837core:PlantMachinerybus:Consolidated2024-03-31SC259837core:FurnitureFittingsbus:Consolidated2024-03-31SC259837core:ComputerEquipmentbus:Consolidated2024-03-31SC259837core:MotorVehiclesbus:Consolidated2024-03-31SC259837bus:Consolidated2024-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssets2024-03-31SC259837core:PlantMachinery2024-03-31SC259837core:FurnitureFittings2024-03-31SC259837core:ComputerEquipment2024-03-31SC259837core:MotorVehicles2024-03-31SC2598372024-03-31SC259837core:LandBuildingscore:OwnedOrFreeholdAssetsbus:Consolidated2024-04-012025-03-31SC259837core:PlantMachinerybus:Consolidated2024-04-012025-03-31SC259837core:FurnitureFittingsbus:Consolidated2024-04-012025-03-31SC259837core:ComputerEquipmentbus:Consolidated2024-04-012025-03-31SC259837core:MotorVehiclesbus:Consolidated2024-04-012025-03-31SC259837core:Subsidiary12024-04-012025-03-31SC259837core:Subsidiary112024-04-012025-03-31SC259837core:CurrentFinancialInstrumentsbus:Consolidated2025-03-31SC259837core:CurrentFinancialInstruments2025-03-31SC259837core:CurrentFinancialInstruments2024-03-31SC259837core:CurrentFinancialInstrumentsbus:Consolidated12025-03-31SC259837core:CurrentFinancialInstrumentsbus:Consolidated12024-03-31SC259837core:CurrentFinancialInstruments22025-03-31SC259837core:CurrentFinancialInstruments32025-03-31SC259837core:WithinOneYearbus:Consolidated2025-03-31SC259837core:WithinOneYearbus:Consolidated2024-03-31SC259837core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-31SC259837core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-31SC259837core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2025-03-31SC259837core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-03-31SC259837core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-31SC259837core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-31SC259837core:Non-currentFinancialInstrumentsbus:Consolidated2025-03-31SC259837core:Non-currentFinancialInstrumentsbus:Consolidated2024-03-31SC259837core:Non-currentFinancialInstruments2025-03-31SC259837core:Non-currentFinancialInstruments2024-03-31SC259837core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-03-31SC259837core:WithinOneYear2025-03-31SC259837core:WithinOneYear2024-03-31SC259837core:BetweenTwoFiveYearsbus:Consolidated2025-03-31SC259837core:BetweenTwoFiveYearsbus:Consolidated2024-03-31SC259837core:BetweenTwoFiveYears2025-03-31SC259837core:BetweenTwoFiveYears2024-03-31SC259837bus:PrivateLimitedCompanyLtd2024-04-012025-03-31SC259837bus:FRS1022024-04-012025-03-31SC259837bus:Audited2024-04-012025-03-31SC259837bus:ConsolidatedGroupCompanyAccounts2024-04-012025-03-31SC259837bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP